. 2025 Apr 9;19(4):e0012993. doi: 10.1371/journal.pntd.0012993

Table 6. Logistic models to high^* neutralizing antibody titer for yellow fever 30–45 days after vaccination in children (between 9 months and 4 years) (n = 339).

Variables	Crude OR (95% CI)	Adjusted OR^** (95% CI)
μFRNT dengue pre-vaccination
Positive	0.72 (0.47–1.11)	0.57 (0.32–0.99)
Negative	1	1
PRNT₉₀ Zika pre-vaccination
Positive	0.95 (0.61–1.45)	1.04 (0.59–1.85)
Negative	1	1
Age (months)	1.01 (0.99–1.03)	1.02 (1.00–1.04)

Pre-vaccine yellow fever seropositive individuals and individuals who had seronegative and indeterminate titers 30–45 days post-vaccination were excluded; Data from the subsample of participants tested for μFRNT dengue and PRNT₉₀ Zika.

Reference category: μFRNT YF ≤ 912 (low).

^**

Model adjusted by μFRNT dengue pre-vaccination, PRNT₉₀ Zika pre-vaccination, Age (months) and sex: AIC = 468.

Table 6. Logistic models to high* neutralizing antibody titer for yellow fever 30–45 days after vaccination in children (between 9 months and 4 years) (n = 339).

Table 6. Logistic models to high^* neutralizing antibody titer for yellow fever 30–45 days after vaccination in children (between 9 months and 4 years) (n = 339).